# 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

> **NCT04379713** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1511 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** 20-valent pneumococcal conjugate vaccine
- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine

## Key facts

- **NCT ID:** NCT04379713
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-21
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 1511 (ACTUAL)
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04379713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04379713, "20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04379713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*